Laurel Wealth Advisors LLC Purchases 7,371,687 Shares of Johnson & Johnson $JNJ

Laurel Wealth Advisors LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 15,040.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,420,699 shares of the company’s stock after buying an additional 7,371,687 shares during the period. Laurel Wealth Advisors LLC owned about 0.31% of Johnson & Johnson worth $1,133,512,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. RiverFront Investment Group LLC raised its stake in shares of Johnson & Johnson by 41.2% during the 2nd quarter. RiverFront Investment Group LLC now owns 14,921 shares of the company’s stock worth $2,279,000 after purchasing an additional 4,355 shares in the last quarter. One Charles Private Wealth Services LLC raised its holdings in Johnson & Johnson by 8.4% in the 2nd quarter. One Charles Private Wealth Services LLC now owns 3,410 shares of the company’s stock valued at $521,000 after acquiring an additional 265 shares during the period. Steward Partners Investment Advisory LLC lifted its holdings in Johnson & Johnson by 0.8% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 364,515 shares of the company’s stock worth $55,680,000 after purchasing an additional 2,740 shares during the last quarter. Clifford Capital Partners LLC grew its stake in shares of Johnson & Johnson by 19.8% in the second quarter. Clifford Capital Partners LLC now owns 144,684 shares of the company’s stock valued at $22,100,000 after acquiring an additional 23,958 shares in the last quarter. Finally, Jaffetilchin Investment Partners LLC raised its position in shares of Johnson & Johnson by 3.6% in the second quarter. Jaffetilchin Investment Partners LLC now owns 37,598 shares of the company’s stock valued at $5,743,000 after buying an additional 1,298 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several analyst reports. Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Scotiabank assumed coverage on shares of Johnson & Johnson in a report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 target price on the stock. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Finally, Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Four research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $206.07 on Tuesday. The stock has a market cap of $496.48 billion, a PE ratio of 19.89, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $206.94. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The business has a fifty day simple moving average of $188.83 and a 200-day simple moving average of $172.13.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.